Loading clinical trials...

COMPLETEDPHASE1

Pharmacokinetic Study on Raltegravir and Lamotrigine

The Influence of Raltegravir (MK-0518) on the Pharmacokinetics of Single-dose Lamotrigine in Healthy Male Subjects (GRANOLA)

NCT00618241•Radboud University Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether interactions between raltegravir and lamotrigine take place and to study the safety of the combination raltegravir/lamotrigine before used in HIV patients.

Detailed Description

Lamotrigine is an anticonvulsive drug that is used both for the treatment of HIV-associated neuropathic pain and the treatment of epilepsy in HIV-infected individuals. Lamotrigine is metabolized via glucuronidation. Raltegravir is a newly developed integrase inhibitor that is also metabolized via glucuronidation. Since both agents are metabolized via glucuronidation, there is a possibility of competition for glucuronidation, leading to drug-drug interactions between raltegravir and lamotrigine. This primary objective of this study is to determine the effect of raltegravir on the pharmacokinetics of single dose lamotrigine (by intrasubject comparison). A secondary objective is to determine the effect of single dose lamotrigine on the pharmacokinetics of raltegravir when compared to historical controls. Another secondary objective is to evaluate the safety of combined use of single dose lamotrigine and raltegravir.

Eligibility

Age

18 - 55 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Between 18 and 55 years of age
•Subject does not smoke more than 10 cigarettes, 2 cigars or 2 pipes per day
•Subject has a Quetelet Index of 18 to 30 kg/m2
•Subject is able and willing to sign informed consent
•Subject is in good age-appropriate health condition
•Subject has a normal blood pressure and pulse rate

Exclusion Criteria

•History of sensitivity/idiosyncrasy to medicinal products or excipients
•Positive HIV test
•Positive hepatitis B or C test
•Therapy with any drug (2 weeks preceding dosing) except for paracetamol
•Relevant history or presence of pulmonary disorders, cardiovascular
•History of or current abuse of drugs, alcohol or solvents
•Inability to understand the nature and extent of the trial and procedures
•Participation in a drug trial within 60 days prior to the first dose
•Donation of blood within 60 days prior to the first dose
•Febrile illness within 3 days before the first dose

Locations (1)

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

Key Dates

Start Date

February 1, 2008

Primary Completion Date

October 1, 2008

Completion Date

October 1, 2008

Last Updated

October 19, 2020

Enrollment

ACTUAL participants

Conditions

HIV Infection

Interventions

lamotrigine

DRUG

Raltegravir

DRUG

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

RECRUITING

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacokinetic Study on Raltegravir and Lamotrigine

Inclusion Criteria

Exclusion Criteria

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Skeletal Muscle Energetics and Fatiguability in Older Individuals

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Comprehensive HIV and Harm Prevention Via Telehealth